Table 1.
Patient Characteristics
| RT (n=53, %) | TKI (n=40, %) | P | |
|---|---|---|---|
| Age at BM (years) | |||
| >60 | 20 (38) | 18 (45) | 0.331 |
| 50-60 | 15 (28) | 14(35) | |
| <50 | 18 (34) | 8 (20) | |
| Gender | |||
| Male | 25 (47) | 19 (48) | 0.975 |
| Female | 28 (53) | 21 (52) | |
| KPS | |||
| 70-80 | 43 (81) | 28 (70) | 0.211 |
| 90-100 | 10 (19) | 12 (30) | |
| Smoking history | |||
| No | 35 (66) | 24 (60) | 0.549 |
| Yes | 18 (34) | 16 (40) | |
| Number of BMs | |||
| 1-3 | 24 (45) | 22 (55) | 0.645 |
| 4-10 | 23 (43) | 14 (35) | |
| >10 | 6 (12) | 4 (10) | |
| Extracranial metastases at the time of BM | |||
| Yes | 30 (55) | 28 (70) | 0.187 |
| No | 23 (45) | 12 (30) | |
| Stage at diagnose | |||
| I-III | 17 (32) | 7 (18) | 0.112 |
| IV | 36 (68) | 33 (82) | |
| Largest size of BM | |||
| ≤10 mm | 13 (25) | 17 (43) | 0.066 |
| >10 mm | 40 (75) | 23 (57) | |
| Disease-specific GPA | |||
| 0-1.5 | 24 (45) | 21 (53) | 0.491 |
| 2.0-4.0 | 29 (55) | 19 (47) | |
| Symptom from BM | |||
| No | 33 (62) | 32 (80) | 0.065 |
| Yes | 20 (38) | 8 (20) | |
| EGFR mutation | |||
| Exon 19 deletion | 28 (53) | 21 (53) | 0.975 |
| Exon 21 L858R and others | 25 (47) | 19 (47) | |
| EGFR-TKI | |||
| Gefitinib | 34 (64) | 21 (53) | 0.288 |
| Erlotinib | 12 (23) | 8 (20) | |
| Afatinib | 0 (0) | 1 (2) | |
| Icotinib | 7 (13) | 10 (25) | |
| Use Osimertinib as salvage treatment | |||
| No | 44 (83) | 32 (80) | 0.709 |
| Yes | 9 (17) | 8 (20) |
Abbreviations: KPS, Karnofsky Performance Score; BM, brain metastasis; GPA, graded prognostic assessment; RT, radiation therapy; TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.